Aquablation therapy for symptomatic benign prostatic hyperplasia: a single‐centre experience in 47 patients

• DOI: 10.1111/bju.14126
• Publication Date: 2018-01-10T17:27:37Z
• Authors: Mihir M. Desai; Abhishek Singh; Shashank Abhishek; Abhishek Laddha; Harshad Pandya; Akbar N. Ashrafi; Arvind P. Ganpule; Claus G. Roehrborn; Andrew J. Thomas; Mahesh Desai; Ravindra B. Sabnis
• Keywords: Urinary retention

To report procedure process improvements and confirm the preserved safety short-term effectiveness of a second-generation Aquablation device for treatment lower urinary tract symptoms (LUTS) attributable to benign prostatic hyperplasia (BPH) in 47 consecutive patients at single institution.Aquablation was performed with symptomatic BPH institution. Baseline, peri-operative 3-month function data were collected.The mean (range) patient age 66 (50-79) years, transrectal ultrasonography-measured prostate volume 48 (20-118) mL. A median lobe present 25 (53%) eight had catheter-dependent retention. The total time 35 (13-128) min tissue resection 4 (1-10) min. Five Clavien-Dindo grade I/II five III complications recorded patients. hospital stay 3.1 (1-8) days duration urethral catheterization 1.9 (1-11) days. International Prostate Symptom Score (IPSS) decreased from 24.4 baseline 5 3 months; IPSS quality-of-life score 4.5 0.3 points; peak flow rate increased 7.1 16.5 mL/s post-void residual urine 119 43 mL (all P < 0.01).This study confirmed resulting system enhancements, preservation during use LUTS attibutable largest single-institution conducted date.